IRA Drug Pricing Implementation

The drug pricing reforms mandated in the Inflation Reduction Act (IRA) will have far-reaching effects on patients, health care providers, and the pharmaceutical industry. This panel will delve into the complexities of the IRA’s drug pricing provisions and explore how the new regulations will affect access, innovation, and costs. Health policy experts will analyze the potential benefits and challenges of the policy and what they mean for the future.

Session participants include:

Gregg Girvan, Resident Fellow, FREOPP (moderator)

Ge Bai, Professor, Johns Hopkins Carey Business School and Johns Hopkins Bloomberg School of Public Health

Richard Frank, Director-Center on Health Policy, Brookings Institution

Jacob Brody, Co-Founder & CEO, ZorroCard